Valeritas Holdings Revenue Growth Rates (VLRX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Valeritas Holdings Inc.  (VLRX)
 

VLRX's Revenue Growth by Quarter and Year

Valeritas Holdings's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VLRX Revenue (in millions $) FY 2019 FY 2018 FY 2017 FY 2016
4th Quarter December -
3rd Quarter September 8.46
2nd Quarter June 7.51
1st Quarter March 6.40
FY 22.37

VLRXs Annual Revenue
Valeritas Holdings's Revenue in the fiscal year 2018 $ 26.40 millions
Valeritas Holdings's Revenue in the fiscal year 2017 $ 20.25 millions
Valeritas Holdings's Revenue in the fiscal year 2016 $ 19.55 millions
Valeritas Holdings's Revenue in the fiscal year 2015 $ 0.00 millions
Valeritas Holdings's Revenue in the fiscal year 2014 $ 0.00 millions




VLRX Revenue third quarter 2019 Y/Y Growth Comment
Valeritas Holdings Inc. reported Revenue improvement of 22.12% year on year in the third quarter 2019, to $ 8.46 millions, this is lower than Valeritas Holdings Inc.'s recent average Revenue surge of 349066.53%.

Looking into third quarter 2019 results within Medical Equipment & Supplies industry 54 other companies have achieved higher Revenue growth. While Valeritas Holdings Inc.' s Revenue rise of 22.12% ranks overall at the positon no. 922 in the third quarter 2019.


VLRX Revenue ( Y/Y Growth %) 2019
 2018 2017 2016
4th Quarter December - 19.2 % 20.42 % -
3rd Quarter September 22.12 % 36.69 % 4.32 % 2.53 %
2nd Quarter June 15.54 % 35.7 % -2.04 % 6.3 %
1st Quarter March 5.26 % 31.89 % -7.98 % -
FY   - 30.37 % 3.53 % -

Financial Statements
Valeritas Holdings's third quarter 2019 Revenue $ 8.46 millions VLRX's Income Statement
Valeritas Holdings's third quarter 2018 Revenue $ 6.93 millions Quarterly VLRX's Income Statement


VLRX Revenue (Quarter on Quarter Growth %)

 2019
 2018 2017 2016
4th Quarter December - -0.58 % 14 % -1.23 %
3rd Quarter September 12.69 % 6.62 % 5.85 % -0.61 %
2nd Quarter June 17.34 % 6.91 % 3.9 % -2.4 %
1st Quarter March -7.11 % 5.19 % -3.96 % -
FY (Year on Year)   - 30.37 % 3.53 % -


Back to VLRX Growth rate Comparisons >> Back to VLRX Growth rate Comparisons >>


Revenue third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #55
Healthcare Sector #225
Overall #922

Revenue Y/Y Growth Statistics
High Average Low
2429900 % 349066.53 % -50 %
(Sep 30 2016)   (Jun 30 2017)
Revenue third quarter 2019 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #55
Healthcare Sector #225
Overall #922
Revenue Y/Y Growth Statistics
High Average Low
2429900 % 349066.53 % -50 %
(Sep 30 2016)   (Jun 30 2017)

Revenue by Quarter for the Fiscal Years 2016, 2017, 2018, 2019

Valeritas Holdings's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
2123813.04 % 151735.27 % -81.48 %
(Jun 30 2016)  


VLRX's III. Quarter Q/Q Revenue Comment
Valeritas Holdings Inc. achieved in the III. Quarter 2019 below company average Revenue rise of 12.69% quarter on quarter, to $ 8.46 millions.

Although the III. Quarter 2019 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the 6.62% growth in the III. Quarter a year ago

Within Medical Equipment & Supplies industry 6 other companies have achieved higher Revenue quarter on quarter growth. While Valeritas Holdings's Revenue growth quarter on quarter, overall rank is 355.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #7
Healthcare Sector #89
Overall #355
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #7
Healthcare Sector #89
Overall #355
Revenue Q/Q Growth Statistics
High Average Low
2123813.04 % 151735.27 % -81.48 %
(Jun 30 2016)  


VLRX's III. Quarter Q/Q Revenue Comment
Valeritas Holdings Inc. achieved in the III. Quarter 2019 below company average Revenue rise of 12.69% quarter on quarter, to $ 8.46 millions.

III. Quarter 2019 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 6.62% in the III. Quarter a year ago.

Within Medical Equipment & Supplies industry 6 other companies have achieved higher Revenue quarter on quarter growth. While Valeritas Holdings's Revenue growth quarter on quarter, overall rank is 355.


Valeritas Holdings's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2019)		 12 Months Ending
(Jun 30 2019)		 12 Months Ending
(Mar 31 2019)		 12 Months Ending
(Dec 31 2018)		 12 Months Ending
(Sep 30 2018)
Cumulative Revenue 12 Months Ending $ 29.27 $ 27.74 $ 26.72 $ 26.40 $ 25.29
Y / Y Revenue Growth (TTM) 15.78 % 18.41 % 23.05 % 30.39 % 31.28 %
Year on Year Revenue Growth Overall Ranking # 57 # 549 # 458 # 59 # 2964
Seqeuential Revenue Change (TTM) 5.54 % 3.81 % 1.22 % 4.4 % 7.94 %
Seq. Revenue Growth (TTM) Overall Ranking # 1482 # 1667 # 784 # 645 # 2588


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2019 period, Valeritas Holdings's cumulative twelve months Revenue were $ 29 millions, company would post below average annual Revenue growth of 7.94% year on year, if the fiscal year would end at Sep 30 2019.
A slow-down in the Valeritas Holdings's Revenue growth from the 7.51% growth in Jun 30 2019.

Among companies within the Healthcare sector 16 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 57, from total ranking in previous quarter at 549.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 69
Healthcare Sector # 17
Overall # 57

Revenue TTM Y/Y Growth Statistics
High Average Low
8802073.91 %
 821348.78 %
-88.27 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 69
Sector # 253
S&P 500 # 1482
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2019 period, Valeritas Holdings's cumulative twelve months Revenue were $ 29 millions, company would post below average annual Revenue growth of -88.27% year on year, if the fiscal year would end at Sep 30 2019.
A slow-down in the Valeritas Holdings's Revenue growth from the 7.51% growth in Jun 30 2019.

Among companies within the Healthcare sector 16 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 57, from total ranking in previous quarter at 549.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 69
Healthcare Sector # 17
Overall # 57

Revenue TTM Y/Y Growth Statistics
High Average Low
8802073.91 %
821348.78 %
-88.27 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 69
Sector # 253
S&P 500 # 1482




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VLRX's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2019 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2019
Orchard Therapeutics Plc38.28%$ 38.284 millions
Societal Cdmo Inc 38.13%$ 38.134 millions
Immucell Corporation37.92%$ 37.922 millions
Avedro Inc37.77%$ 37.765 millions
Avalo Therapeutics Inc 37.76%$ 37.756 millions
Tactile Systems Technology Inc 36.59%$ 36.589 millions
Vericel Corporation35.65%$ 35.648 millions
Syros Pharmaceuticals Inc 35.44%$ 35.437 millions
Interpace Biosciences Inc 34.28%$ 34.278 millions
Durect Corp33.93%$ 33.935 millions
Surmodics Inc 33.76%$ 33.762 millions
Harpoon Therapeutics Inc 33.30%$ 33.302 millions
Ptc Therapeutics inc 33.26%$ 33.261 millions
Glaukos Corp33.25%$ 33.254 millions
Sientra Inc 32.81%$ 32.812 millions
Genmark Diagnostics Inc 32.43%$ 32.434 millions
Oxford Immunotec Global Plc32.21%$ 32.206 millions
Veracyte Inc 31.99%$ 31.991 millions
Intercept Pharmaceuticals inc 31.85%$ 31.848 millions
Adamas Pharmaceuticals Inc31.28%$ 31.282 millions
Orthopediatrics Corp31.13%$ 31.125 millions
Northwest Biotherapeutics Inc30.91%$ 30.905 millions
Iradimed Corporation30.84%$ 30.844 millions
Vivosim Labs Inc 30.43%$ 30.435 millions
Thermogenesis Holdings Inc 30.36%$ 30.357 millions
Acceleron Pharma inc29.16%$ 29.159 millions
Infusystem Holdings Inc28.85%$ 28.854 millions
Icad Inc28.55%$ 28.553 millions
Cyclo Therapeutics Inc 27.37%$ 27.367 millions
Insulet Corporation27.16%$ 27.164 millions


About Valeritas Holdings Revenue Growth Rates (VLRX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.